Literature DB >> 9390590

Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators.

A Laupacis1, D Fergusson.   

Abstract

UNLABELLED: Concern about the side effects of allogeneic red blood cell transfusion has increased interest in methods of minimizing perioperative transfusion. We performed meta-analyses of randomized trials evaluating the efficacy and safety of aprotinin, desmopressin, tranexamic acid, and epsilon-aminocaproic acid in cardiac surgery. All identified randomized trials in cardiac surgery were included in the meta-analyses. The primary outcome was the proportion of patients who received at least one perioperative allogeneic red cell transfusion. Sixty studies were included in the meta-analyses. The largest number of patients (5808) was available for the meta-analysis of aprotinin, which significantly decreased exposure to allogeneic blood (odds ratio [OR] 0.31, 95% confidence interval [CI] 0.25-0.39; P < 0.0001). The efficacy of aprotinin was not significantly different regardless of the type of surgery (primary or reoperation), aspirin use, or reported transfusion threshold. The use of aprotinin was associated with a significant decrease in the need for reoperation because of bleeding (OR 0.44, 95% CI 0.27-0.73; P = 0.001). Desmopressin was not effective, with an OR of 0.98 (95% CI 0.64-1.50; P = 0.92). Tranexamic acid significantly decreased the proportion of patients transfused (OR 0.50, 95% CI 0.34-0.76; P = 0.0009). Epsilon-aminocaproic acid did not have a statistically significant effect on the proportion of patients transfused (OR 0.20, 95% CI 0.04-1.12; P = 0.07). There were not enough patients to exclude a small but clinically important increase in myocardial infarction or other side effects for any of the medications. We conclude that aprotinin and tranexamic acid, but not desmopressin, decrease the number of patients exposed to perioperative allogeneic transfusions in association with cardiac surgery. IMPLICATIONS: Aprotinin, desmopressin, tranexamic acid, and epsilon-aminocaproic acid are used in cardiac surgery in an attempt to decrease the proportion of patients requiring blood transfusion. This meta-analysis of all published randomized trials provides a good estimate of the efficacy of these medications and is useful in guiding clinical practice. We conclude that aprotinin and tranexamic acid, but not desmopressin, decrease the exposure of patients to allogeneic blood transfusion perioperatively in relationship to cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390590     DOI: 10.1097/00000539-199712000-00014

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  49 in total

Review 1.  Desmopressin for minimising perioperative allogeneic blood transfusion.

Authors:  P A Carless; D A Henry; A J Moxey; D O'Connell; B McClelland; K M Henderson; K Sly; A Laupacis; D Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 2.  Cell salvage for minimising perioperative allogeneic blood transfusion.

Authors:  Paul A Carless; David A Henry; Annette J Moxey; Dianne O'Connell; Tamara Brown; Dean A Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 3.  Antifibrinolytic therapy: evidence, bias, confounding (and politics!).

Authors:  Paul Myles
Journal:  J Extra Corpor Technol       Date:  2007-12

4.  Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04-20       Impact factor: 3.443

5.  Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

6.  Regulatory decisions pertaining to aprotinin may be putting patients at risk.

Authors:  Paul C Hébert; Dean A Fergusson; Brian Hutton; C David Mazer; Stephen Fremes; Morris Blajchman; Charles MacAdams; George Wells; Jim Robblee; Jean Bussières; Kevin Teoh
Journal:  CMAJ       Date:  2014-09-29       Impact factor: 8.262

Review 7.  [Management of bleeding disorders in intensive care medicine].

Authors:  S Petros
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-23       Impact factor: 0.840

8.  Management of bleeding following major trauma: an updated European guideline.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Philip F Stahel; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2010-04-06       Impact factor: 9.097

9.  A Comparative Study to Determine the Effect of Intravenous Magnesium on Postoperative Bleeding after on Pump CABG in Patients Receiving Pre-Operative Aspirin.

Authors:  Sampa Dutta Gupta; Soumendu Pal; Anupam Goswami; Sandip Bhadra; Sripurna Mandal; Chandashi Naskar; Sudakshina Mukherjee; Debasish Boral
Journal:  Indian J Anaesth       Date:  2009-04

Review 10.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.